ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1013

Estimating the Monetary Value of  annual Productivity Gained in Early Active RA Patients Receiving Etanercept Plus Methotrexate: Results From the Prize Study

Wei Zhang1, Nick Bansback2, Huiying Sun1, Ronald Pedersen3, Sameer Kotak4 and Aslam H. Anis1,2, 1St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 2School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 3Specialty Care, Pfizer Inc, Collegeville, PA, 4Specialty Care, Pfizer Inc., New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: economics and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Determining the effect of treatment on work productivity of subjects with rheumatoid arthritis (RA) is an important topic given that most sufferers develop the disease between 35 to 50 years of age and many experience functional loss that translates into reduced productivity and work disability. The Valuation of Lost Productivity (VOLP) is a validated instrument developed to estimate productivity impacts from a societal perspective according to the human capital (economic) approach to measuring worker productivity. The VOLP was included in the PRIZE trial: a phase IV, 121-week, prospective, 3-phase (open-label followed by randomized double-blind, and tapering/observational phases), parallel-group, multicenter, outpatient study.

Objective: To assess productivity changes (gains), as measured by the VOLP, in phase 1 of the PRIZE trial.

Methods: In Phase 1, MTX- and biologic-naïve patients with early, active RA (symptom onset ≤12 months from enrollment; DAS28 >3.2) received open-label ETN50/MTX for 52 weeks. The VOLP was completed approximately every 13 weeks. The changes in three main VOLP outcomes from baseline to week 52 were measured: 1) 3-month paid work productivity gains, the sum of increased worked hours after adjusting for absenteeism, presenteeism and employment status changes; 2) 7-day unpaid work productivity impact; 3) Total 3-month monetary productivity gains as the sum of paid and unpaid work productivity gains. Productivity impacts included direct impact of a worker’s own productivity as well as the spillover effect when team productivity is impacted and/or substitute worker productivity is considered. Bootstrapping methods were used to test the changes in VOLP outcomes.

Results: A total of 196 patients were employed at baseline and had at least one scheduled follow-up visit. The average age was 46 years and 68% were female. The patients had a high disease activity (DAS28=5.91) and moderate functional disability (HAQ=1.22). The paid work loss was about 111.7 hours in the past 3 months at baseline and decreased to 60.1 hours at week 52, with a gain of 33.43 hours per 3 months. Similarly, the gain in unpaid work was about 4 hours per week. Total costs of lost productivity in the past 3 months were €3,483 at baseline and were reduced to €843 at week 52, with total monetary gains of €1322 per 3 months. All the three main VOLP outcomes were improved significantly over the 52 weeks.

Conclusion:  Combination therapy with ETN50/MTX was associated with a significant productivity gain for patients with early RA who were still observed at week 52.

Outcomes

Week0

Week52

Gains†

P value†

Employed (N)

196

143

 

 

Paid work productivity loss in the past 3 months (N)

162

135

 

 

Paid work loss, hours (SD)

111.71 (116.84)

60.11 (140.91)

33.43(164.41)

0.035

Unpaid work productivity loss in the past 7 days (N)

167

143

 

 

Unpaid work loss, hours (SD)

6.27 (11.11)

1.79 (5.86)

4.22(12.33)

0.001

Total costs of lost productivity in the past 3 months (N)

141

124

 

 

Total costs , € (SD)

3483.48 (8482.03)

842.77 (2242.33)

1322.42(4378.08)

0.017

Bolded values are the numbers of non-missing values used to generate the outcomes below

† for patients whose outcomes at week 0 and week 52 were both observed



Disclosure:

W. Zhang,
None;

N. Bansback,
None;

H. Sun,
None;

R. Pedersen,

Pfizer Inc,

3;

S. Kotak,

Pfizer Inc,

3;

A. H. Anis,

Pfizer Inc,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/estimating-the-monetary-value-of-annual-productivity-gained-in-early-active-ra-patients-receiving-etanercept-plus-methotrexate-results-from-the-prize-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences